With tremendous technological advancements, traditional retailing has progressively been transformed into an omnichannel retail environment. While making an appeal to the behavioral reasoning theory, this paper explicates consumers’ (hedonic and utilitarian) value expectations and behavioral reasoning patterns as key antecedents of the maturing of their webrooming intentions in omnichannel environments. Performing PLS-based structural equation modeling on survey data obtained from 470 consumers, it has been found that both the (perceived) value and behavioral reasoning patterns of the consumers exhibit significant direct and indirect effects on building favorable attitudes toward webrooming that eventually lead to the culmination of pro-webrooming intentions. Besides expanding our understanding of the phenomena of interest, this study offers useful insights to marketers/retailers on how to boost pro-webrooming attitudes, intentions, and behaviors by ensuring a superior alignment with (utilitarian and hedonic) value perceptions and pro- and counter-webrooming reasoning patterns of the consumers.
31 December 2021 in Pakistan Armed Forces Medical Journal
Objective: To investigate the effect of unilateral intravitreal Bevacizumab on contralateral eye in bilateral diabetic macular edema. Study Design: Quasi-experimental study. Place and Duration of Study: Retina Department of Al-Shifa Trust Eye Hospital, Rawalpindi, from Sep to Dec 2020. Methodology: Thirty-two patients were enrolled with consecutive sampling. All the patients had clinically diagnosed diabetic macular edema having >275µm macular thickness on OCT. They were injected with 1.25mg/0.05mL of Bevacizumab in one eye. Baseline macular thickness was compared with 4 weeks follow up macular thickness, using Optical Coherence Tomography. Results: The central macular thickness in the untreated eye at baseline was 396.97 ± 29.79 µm and 388.34 ± 30.06 µm at 4 weeks (p-value=0.001). The difference in central macular thickness in treated and untreated eyes were 28.44 ± 4.11 µm and 19.81 ± 5.31 µm respectively (p-value = 0.001). There were statistically significant differences between these measurements. Conclusion: Injecting Bevacizumab in one eye for diabetic macular edema has statistically significant effect on the contralateral non-injected eye macular thickness.